Annexon reports early positive FORWARD study data for tanruprubart in GBS patients
Annexon reported early results from the first ten U.S. and European patients in its open-label FORWARD study of tanruprubart for Guillain-Barré syndrome (GBS), stating that all treated patients showed rapid, clinically meaningful improvement in strength. The company said it plans to submit a Biologics License Application (BLA) in Q4 2026, and the drug is under review by the European Medicines Agency. The update is clinical and early, without financial results, and its impact on shareholders depends on later data and regulatory outcomes.
Key points
- First ten U.S. and European patients in the FORWARD study (n=10) were reported
- All treated patients showed rapid improvement in muscle strength within four days, per the company
- Planned Biologics License Application (BLA) submission is targeted for Q4 2026
- Tanruprubart is currently under review by the European Medicines Agency (EMA)
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.